Brown, Lisle/Cummings’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
DAM
F
Brown, Lisle/Cummings's NVO Position: Q1 2026 in Review
Brown, Lisle/Cummings increased its Novo Nordisk (NVO) stake by 0.18% in Q1 2026, buying an estimated $5.17K and bringing the position to 59,204 shares worth $2.18M. The position accounts for 0.54% of the portfolio, ranked #44.
Brown, Lisle/Cummings first reported a position in NVO in Q4 2021 and has held it in 18 quarters since. The position peaked at $6.14M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Brown, Lisle/Cummings held 59,204 shares of Novo Nordisk worth $2.18M as of Q1 2026.
- Brown, Lisle/Cummings bought 109 Novo Nordisk shares in Q1 2026, an estimated $5.17K.
- Novo Nordisk made up 0.54% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #44 holding.
- Brown, Lisle/Cummings first reported a position in Novo Nordisk in Q4 2021 and has held it in 18 quarters since.
- Brown, Lisle/Cummings's Novo Nordisk position peaked at $6.14M in Q2 2024.
- 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.